Safety and Tolerability of Once Versus Twice Daily Atomoxetine in Adults with ADHD
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Attention-Deficit/Hyperactivity Disorder (ADHD) is a disorder characterized by hyperactivity, impulsiveness, and inattention that affects 4% of adults. Atomoxetine hydrochloride is an FDA-approved treatment for adult ADHD, but no studies have clarified whether there are advantages to once versus twice daily dosing. METHODS: This randomized, double-blind, multicenter study compared safety and tolerability of 80 mg atomoxetine QD versus 40 mg atomoxetine BID in 218 adults with ADHD. Treatment-emergent adverse events (TEAEs), laboratory values, vital signs, weight, electrocardiograms, scores on the Arizona Sexual Experiences Scale, and efficacy (using the Conners' ADHD Rating Scale-Investigator Rated: Screening Version) were assessed. RESULTS: The overall incidence for any one TEAE was low. There was no significant treatment group difference in likelihood of patients experiencing >/=1 of the four most commonly observed TEAEs (dry mouth, insomnia, nausea, and erectile dysfunction). Frequency of nausea was significantly lower in the 40 mg BID group (16.4%) than the 80 mg QD group (32.4%; p = .007). There were no unexpected safety results. Although both QD and BID treatments were efficacious, the reduction in scores was greater for BID treatment. CONCLUSIONS: Data indicate both dosing strategies are safe, well tolerated, and efficacious in the treatment of adult ADHD. Changes in dosing strategy are unlikely to be accompanied by safety risks, implying that there is room for prescribers to use discretion and to base dosing strategies on individual factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1792 · Cited by 950
Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. A., Allen, A. J., Kelsey, D., Wernicke, J., Dietrich, A., & Milton, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01671-2 · Cited by 790
Self-citationAttention deficit hyperactivity disorder adults: Comorbidities and adaptive impairments
Murphy, K., & Barkley, R. A. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90022-x · Cited by 700
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Self-citationWENDER, P. H., WOLF, L. E., & WASSERSTEIN, J. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05770.x · Cited by 498
Cited by
Adler, L. A., Liebowitz, M., Kronenberger, W., Qiao, M., Rubin, R., Hollandbeck, M., Deldar, A., Schuh, K., & Durell, T. (2009) · Depression and Anxiety · doi:10.1002/da.20549 · Cited by 176
“Other studies have confirmed these results in adults([13]) and examined the usefulness of ATX in treating ADHD in the presence of comorbid alcohol use disorders.”
ResultSelf-citationAdler, L. A., Sutton, V. K., Moore, R. J., Dietrich, A. P., Reimherr, F. W., Sangal, R. B., Saylor, K. E., Secnik, K., Kelsey, D. K., & Allen, A. J. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000239797.21826.70 · Cited by 79
“main study, a double-blind design (without placebo control) used to assess the safety and efficacy of once-daily versus twice-daily treatment with atomoxetine, is published in another reference.(13) The present analysis pertains to the same 6-week portion of the trial but focuses on data related to the quality of life.”
MethodSelf-citationSantosh, P. J., Sattar, S., & Canagaratnam, M. (2011) · CNS Drugs · doi:10.2165/11593070-000000000-00000 · Cited by 62
Effect of Atomoxetine on Executive Function Impairments in Adults With ADHD
Brown, T. E., Holdnack, J., Saylor, K., Adler, L., Spencer, T., Williams, D. W., Padival, A. K., Schuh, K., Trzepacz, P. T., & Kelsey, D. (2011) · Journal of Attention Disorders · doi:10.1177/1087054709356165 · Cited by 59
“Other studies have confirmed the efficacy for treating core ADHD symptoms in adults (Adler et al., 2006) and shown the usefulness of atomoxetine for treating ADHD in adults with comorbid alcohol use disorders (Wilens et al.”
BackgroundSelf-citationSchein, J., Adler, L. A., Childress, A., Gagnon-Sanschagrin, P., Davidson, M., Kinkead, F., Cloutier, M., Guérin, A., & Lefebvre, P. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.21290 · Cited by 56
Self-citation
Metadata
- Authors
- Adler, L., Dietrich, A., Reimherr, F. W., Taylor, L. V. M., Sutton, V. K., Bakken, R., Allen, A. J., & Kelsey, D.
- Venue
- Annals of Clinical Psychiatry
- Publisher
- SAGE Publications
- Published
- 2006-05-01
- Volume
- 18
- Issue
- 2
- Pages
- 107-113
- ISSN
- 1040-1237 (ISSN-L)
- 1547-3325
- OpenAlex
- W1979919601
- Cited by
- 53
- References
- 5
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Tolerability of Once Versus Twice Daily Atomoxetine in Adults with ADHD. https://app.cochat.ai/papers/10.1080/10401230600614603
- The paper
- Adler, L., Dietrich, A., Reimherr, F. W., Taylor, L. V. M., Sutton, V. K., Bakken, R., Allen, A. J., & Kelsey, D. (2006). Safety and Tolerability of Once Versus Twice Daily Atomoxetine in Adults with ADHD. Annals of Clinical Psychiatry. https://doi.org/10.1080/10401230600614603
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.